Phaseline

Targets › BMPR2

BMPR2 (Bone morphogenetic protein receptor type-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. (UniProt, Q13873)

Open in Phaseline: the race on BMPR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Diagonal TherapeuticsDIAG723
Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII
ALK1, BMPR2Phase 1Hereditary Hemorrhagic TelangiectasiaNov 2027

Conditions

Hereditary Hemorrhagic Telangiectasia (1)

Modalities

protein or peptide (1)

Companies

Diagonal Therapeutics (1)

Related targets

ALK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.